Grifols, S.A. (GRFS) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Barcelona, Spain. Le PDG actuel est Jose Ignacio Abia Buenache.
GRFS a date d'introduction en bourse 2011-06-02, 23,833 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $7.19B.
Grifols, S.A. is a Barcelona-based biopharmaceutical company founded in 1940 that specializes in the procurement, manufacture, and distribution of plasma-derived therapeutic products and diagnostic solutions. Operating through five primary divisions—Bioscience, Hospital, Diagnostic, Bio Supplies, and Others—the company develops innovative treatments for chronic, rare, and life-threatening diseases, including immunoglobulins, clotting factors, and albumin. Grifols serves a broad customer base spanning hospitals, blood banks, healthcare systems, and diagnostic laboratories worldwide, providing comprehensive solutions for conditions such as hemophilia, immune deficiencies, and infectious diseases. The company maintains a technology collaboration with Mondragon and distributes its products through hospitals, wholesalers, distributors, and national health systems globally.
